Viewing nowNucleophine Tablets (Clopidogrel Hydrogen Sulfate)
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
AhnGuk NewPharm Co., Ltd.

MFDS item code 201801536 · Approved 2018.04.09 · Insurance code 053600700
Relief of symptoms of acute coronary syndrome, improvement of atherosclerotic symptoms, prevention of thrombosis in atrial fibrillation
This medication helps improve symptoms caused by atherosclerosis in adult patients with ischemic stroke, myocardial infarction, or peripheral arterial disease. It is also used to reduce the risk of cardiovascular events, such as death, myocardial infarction, and stroke in patients with acute coronary syndrome (unstable angina, non-Q wave myocardial infarction) following pharmacological treatment or procedures. Additionally, it has an effect in reducing the risk of stroke and thromboembolism in adult patients with atrial fibrillation who have vascular risk factors and are unsuitable for vitamin K antagonist use and have a low risk of bleeding. In summary, this medication is used to improve symptoms and reduce risks of various cardiovascular and cerebrovascular diseases caused by atherosclerosis.
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), initiate treatment with this product on the day of initiation with a loading dose of 300 mg once daily, followed by an oral maintenance dose of 75 mg once daily. In this case, aspirin 75 ~ 325 mg should be administered concomitantly with this product once daily. 3. For patients with atrial fibrillation, administer this product 75 mg orally once daily. In this case, aspirin 75 ~ 100 mg should be administered concomitantly with this product once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This product may be administered with or without food.
This medication prevents platelet aggregation and thereby plays a role in preventing the formation of blood clots. The effectiveness of this medication may be reduced in individuals who genetically have impaired function of a specific enzyme (CYP2C19); in such cases, it may be necessary to alter the treatment approach or substitute with another medication. Furthermore, concurrent use of this medication with drugs that activate the CYP2C19 enzyme may increase drug concentration, elevating the risk of bleeding, thus should be avoided. This medication should not be administered to individuals with allergic reactions or bleeding, severe liver impairment, breastfeeding women, or those with specific genetic issues such as lactose intolerance. Patients at high risk of bleeding or those with bleeding disorders should use this medication cautiously, and if symptoms of bleeding occur during treatment, they must immediately consult a physician. Particularly, patients undergoing surgery should discontinue this medication 5 to 7 days prior to surgery and resume once hemostasis is confirmed. There is an increased risk of bleeding when this medication is used in conjunction with other anticoagulants, so caution is advised. During treatment, it may take longer than usual for bleeding to stop; if bleeding persists or becomes severe, healthcare personnel should be informed immediately. Rarely, this medication may cause thrombocytopenia or serious blood disorders; thus, patients should undergo blood tests if symptoms of infection or bleeding appear. The risks to the fetus during pregnancy are unknown, but there may be an increased risk of bleeding during childbirth; therefore, it is advisable to cease this medication 5 to 7 days prior to delivery or neuraxial blocks. In the case of breastfeeding, as it is uncertain whether this medication is secreted in breast milk, it is recommended to consult with a physician regarding whether to continue breastfeeding or discontinue the medication. Elderly patients or those with reduced renal function may have a higher risk of bleeding, requiring careful monitoring and dose adjustments. In cases of overdose, the risk of bleeding may increase, but there is no specific antidote; if necessary, bleeding can be managed with platelet transfusion. This medication should be kept out of reach of children and should not be transferred to other containers to ensure safety.
Hemorrhage, gastrointestinal bleeding, bleeding requiring hospitalization, purpura, contusion, hematoma, epistaxis, hematoma, hematuria, intraocular hemorrhage, intracranial hemorrhage, major hemorrhage, minor hemorrhage, severe hemorrhage, fatal hemorrhage, hemorrhagic stroke, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, abdominal pain, dyspepsia, diarrhea, nausea, rash, pruritus, chest pain, accidental injury, influenza-like illness, pain, fatigue, edema, hypertension, headache, dizziness, depression, dyspnea, rhinitis, bronchitis, cough, urinary tract infection, syncope, palpitations, asthenia, fever, hernia, heart failure, atrial fibrillation, leg cramps, sensory impairment, neuralgia, sensory disturbance, vertigo, constipation, vomiting, increased liver enzymes, gout, hyperuricemia, arthralgia, arthritis, anxiety, insomnia, anemia, pneumonia, sinusitis, eczema, skin ulcer, cystitis, cataract, conjunctivitis, gynecomastia, hypochromic anemia, leukemia, leukopenia, eosinophilia, confusion, hallucination, altered taste, taste loss, vasculitis, hypotension, bronchospasm, interstitial pneumonia, eosinophilic pneumonia, colitis, pancreatitis, gastritis, stomatitis, hepatitis, acute liver failure, maculopapular rash, erythematous skin rash, urticaria, angioedema, vesicular dermatitis, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms, lichen planus, myalgia, glomerulonephritis, fever, abnormal liver function tests, increased serum creatinine, cholecystitis, hematemesis, spinal hematoma
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air or moisture. The appropriate storage temperature is recommended to be between 1°C and 30°C at room temperature.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowClopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
AhnGuk NewPharm Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Geonil Pharmaceutical Co., Ltd.
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Sama Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
(Co., Ltd.) Korea Pharma

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.